MyTPill: A Novel Strategy to Monitor Antiretroviral Adherence Among HIV+ Prescription Opioid Users

The Ohio State University

Status: Completed

Conditions: HIV-positive Individuals

Treatments: Device: MyTPill, a digital pill

Study type: Observational

Funder types: Other; NIH

Identifiers

NCT03978793

2021X0070

K24DA037109 (U.S. NIH Grant/Contract)

R01DA047236 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

This study compares several different antiretroviral adherence measures, including digital pills, in HIV+ individuals who are maintained on opioid analgesics.

Full description

This study compares digital pills, electronic pill bottles, self-report, and dried blood spots, in measuring adherence to antiretroviral medications containing emtricitabine and tenofovir.

Enrollment: 31 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• HIV+, Viral load >200copies/mL, on single pill containing TDF/FTC, receiving prescription for opioid analgesics

Exclusion criteria

• Severe renal or hepatic disease
• Hypersensitivity to silver, magnesium, or zinc following oral use
• Pregnancy
• non-English speaking
• History of Crohn's disease or Ulcerative Colitis
• History of bowel surgery, gastric bypass, or bowel stricture
• History of gastrointestinal malignancy or radiation to the abdomen.

Trial design

31 participants in 1 patient group

MyTPill

Description:

Participants receive digital pills for three months, have a 2-week washout, then switch to Wisepill.

Treatment:

Device: MyTPill, a digital pill